BROOKS LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 98.8 INR | -1.20% |
|
-6.26% | -31.20% |
| Sales 2022 | 911M 10.92M | Sales 2023 | 632M 7.58M | Capitalization | 1.54B 18.47M |
|---|---|---|---|---|---|
| Net income 2022 | -162M -1.94M | Net income 2023 | -209M -2.51M | EV / Sales 2022 | 2.23 x |
| Net Debt 2022 | 227M 2.72M | Net Debt 2023 | 64.89M 778K | EV / Sales 2023 | 2.54 x |
| P/E ratio 2022 |
-11.1
x | P/E ratio 2023 |
-7.37
x | Employees | 296 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 34.81% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.20% | ||
| 1 week | -6.26% | ||
| Current month | +5.56% | ||
| 1 month | -1.64% | ||
| 3 months | -35.47% | ||
| 6 months | -14.68% | ||
| Current year | -31.20% |
1 week
98.80
105.00
1 month
92.00116.00
Current year
91.25185.70
1 year
57.50185.70
3 years
57.50185.70
5 years
13.85185.70
10 years
13.85194.70
| Managers | Title | Age | Since |
|---|---|---|---|
Prashant Rathi
DFI | Director of Finance/CFO | - | 20-07-23 |
| Compliance Officer | - | 22-11-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 60 | 06-02-28 | |
| Director/Board Member | 55 | 12-05-22 | |
Deepak Mahajan
BRD | Director/Board Member | 54 | 13-09-27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 98.8 | -1.20% | 3 154 |
| 24-04-18 | 100 | -1.96% | 18,224 |
| 24-04-16 | 102 | -1.26% | 2,162 |
| 24-04-15 | 103.3 | -1.99% | 1,748 |
| 24-04-12 | 105.4 | -2.00% | 3,717 |
Delayed Quote NSE India S.E., April 19, 2024 at 07:43 am EDT
More quotes
Brooks Laboratories Limited is an India-based pharmaceutical manufacturing company working on a contract basis. The Company operates through the Pharmaceuticals segment. It manufactures various pharmaceutical dosage forms, including injections, tablets, dry syrup and eye/ear drops. Its products under Carbapenem category includes Imipenem 250mg + Cilastatin 250mg, Imipenem 500mg + Cilastatin 500mg, Meropenem 125mg, Meropenem 250mg, Meropenem 500mg, Meropenem 1000mg, Meropenem 1000mg+Sulbactam 500mg, Meropenem 1000mg+Tazobactam 500mg, Doripenem 500mg and Doripenem 1000mg. It offers Penicillins in the form of injections, tablets and dry syrup. Its General category of products include liquid injections, dry powder injections and eye/ear drops. Its liquid injections include Iron sucrose 100mg/5ml, among others. The Company has manufacturing plants at Baddi, Himachal Pradesh. The Company manufactures and markets the pharmaceuticals nationally and internationally to various regulated markets.
Sector
Pharmaceuticals
Calendar
2024-05-26
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -31.20% | 31.41M | |
| +20.91% | 43.54B | |
| +16.96% | 21.74B | |
| +7.95% | 13.53B | |
| +7.98% | 13.02B | |
| +33.80% | 11.28B | |
| -11.05% | 6.99B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +7.71% | 5.09B |
- Stock Market
- Equities
- BROOKS Stock
